Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells

BACKGROUND: Tamoxifen resistance presents a huge clinical challenge for breast cancer patients. An understanding of the mechanisms of tamoxifen resistance can guide development of efficient therapies to prevent drug resistance. METHODS: We first tested whether peptidylarginine deiminase 2 (PAD2) may...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Fujun, Miao, Lixia, Xue, Teng, Qin, Hao, Mondal, Santanu, Thompson, Paul R., Coonrod, Scott A., Liu, Xiaoqiu, Zhang, Xuesen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785896/
https://www.ncbi.nlm.nih.gov/pubmed/31601253
http://dx.doi.org/10.1186/s13046-019-1404-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785896/
https://www.ncbi.nlm.nih.gov/pubmed/31601253
http://dx.doi.org/10.1186/s13046-019-1404-8

Ejemplares similares